Last $0.0014 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 07/18/14 All times are local (Market data is delayed by at least 15 minutes).

introgen therapeutics inc (INGNQ) Snapshot

Open
$0.0014
Previous Close
$0.0014
Day High
$0.0014
Day Low
$0.0014
52 Week High
07/17/14 - $0.01
52 Week Low
02/19/14 - $0.0001
Market Cap
61.8K
Average Volume 10 Days
140.0
EPS TTM
$-0.21
Shares Outstanding
44.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTROGEN THERAPEUTICS INC (INGNQ)

Related News

No related news articles were found.

introgen therapeutics inc (INGNQ) Related Businessweek News

No Related Businessweek News Found

introgen therapeutics inc (INGNQ) Details

Introgen Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. The company is developing product candidates to treat a range of cancers using tumor suppressors, cytokines, and other targeted molecular therapies. Its lead product candidate include ADVEXIN therapy, which combines the p53 tumor suppressor with a non-replicating, non-integrating, and adenoviral delivery system. ADVEXIN therapy is in Phase III clinical trials in patients with advanced recurrent squamous cell carcinoma of the head and neck. The company’s product candidates also include INGN 241, a Phase I/early Phase II clinical trials completed product to treat patients with solid tumors; and INGN 225, which has completed a Phase I/II clinical trials for patients with small cell lung cancer, and is also in Phase I/II trials in patients with breast cancer. In addition, its product candidates comprise INGN 234, which is in Phase-I clinical trial, for the prevention of oral cancers and the treatment of oral leukoplakia; INGN 401, a Phase I/early Phase II clinical trial product for patients with advanced non-small cell lung cancer; INGN 402 that contains the p53 tumor suppressor; INGN 403 that contains the mda-7 tumor suppressor; and INGN 007, a replication-competent viral therapy. Introgen Therapeutics has collaborative agreements with VirRx, Inc. to investigate replication-competent viral therapies; and Colgate-Palmolive Company to develop and market oral healthcare products. The company was founded in 1993 and is based in Houston, Texas.

80 Employees
Last Reported Date: 03/17/08
Founded in 1993

introgen therapeutics inc (INGNQ) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INGNQ:US $0.00 USD 0.00

INGNQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INGNQ.
View Industry Companies
 

Industry Analysis

INGNQ

Industry Average

Valuation INGNQ Industry Range
No financial data is available for INGNQ.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTROGEN THERAPEUTICS INC, please visit www.introgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.